NON-HODGKIN LYMPHOMA

This study tests a vaccine designed to help stem cell transplant recipients fight off the common CMV virus, which can cause serious illness in people with weakened immune systems. About 100 participants who already had CMV and are getting a donor transplant will receive either th…

This study tests a vaccine called Triplex to see if it can prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be life-threatening for people with weakened immune systems. The vaccine uses three pieces of CMV…

This early-stage trial tests a new treatment called huCART19-IL18 for people with certain blood cancers (leukemia and lymphoma) that have come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them to better recognize…

This study tests a combination of an immunotherapy drug (pembrolizumab) and low-dose radiation for people with non-Hodgkin lymphoma that has come back or not responded to prior treatments. Six participants will receive the drug plus radiation to one or more tumor sites. The goal …

This study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not gone away. Researchers take a patient's own immune cells, train them in a lab to recognize five cancer-specific proteins, and give them back as an infusion. Some adults also …

This early-phase study tests whether the drug duvelisib can help CAR T-cells (engineered immune cells) survive longer in the body after infusion. About 42 adults with non-Hodgkin lymphoma or acute lymphocytic leukemia will receive duvelisib following standard CAR T-cell therapy. …

This study planned to test two drugs—golcadomide and nivolumab—together in adults with non-Hodgkin lymphoma that did not respond or came back after CAR-T cell therapy. The goal was to find a safe dose and see if the combination could shrink tumors. However, the study was withdraw…

This study tests whether adding special immune cells called veto cells can help donor stem cells grow safely after a transplant for blood cancers. The goal is to prevent graft-versus-host disease, where donor cells attack the patient's body. About 16 people aged 12 to 75 with var…

This early-phase study tests an experimental drug called DS-3201b in about 100 adults with non-Hodgkin lymphoma whose cancer has come back or is not responding to current treatments. The main goals are to find a safe dose and see how the drug works in the body. The study also che…

This phase 3 study tests whether a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) works better than a standard chemotherapy regimen for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. About 208 adu…

This early-stage study tests a new treatment called SC291 for people with certain types of blood cancer (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have come back or not responded to other treatments. SC291 is a type of immune cell therapy made from donor cells, d…

This study offers continued access to the drug CC-122 for people with Non-Hodgkin Lymphoma who have already been taking it for more than 5 years in earlier trials and are still benefiting. Only 12 participants are enrolled, and the main goal is to monitor safety and side effects.…

This study tests a drug called acalabrutinib, alone or with other medicines, in people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to see if the drug is safe and helps shrink or control the cancer. About 113 adults took par…

This early-stage study tests a mix of six drugs (called ViPOR-P) in adults with B-cell lymphomas that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. About 34 participants will take pills and receive infusions o…

This early-phase study tests whether giving radiation therapy before standard CAR T cell treatment is safe and practical for people with B-cell lymphoma that has come back or not responded to prior treatments. About 20 participants will receive split-course bridging radiation to …

This early-stage study tests a new treatment for people with non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The approach uses a patient's own T cells, which are modified in a lab to recognize and attack cancer cells, then infused back in…

This early-phase study tests whether vaccinating stem cell donors against cytomegalovirus (CMV) can prevent the virus from causing problems in blood cancer patients after a transplant. About 34 donor-recipient pairs are taking part. The vaccine is given to the donor before stem c…

This study looks at whether adding acupuncture to standard pain care can reduce the need for strong opioid painkillers in people with multiple myeloma, Hodgkin disease, or non-Hodgkin lymphoma who are getting high-dose chemotherapy. About 299 adults will be randomly assigned to r…

This study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observat…

This study looks at how blood cancers and stem cell transplants affect muscle function in 144 patients. Researchers want to see if muscle health can help predict recovery and complications after transplant. The goal is to better understand and support patients through their treat…